Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Blood (2023) 142 (Supplement 1): 4867.

https://doi.org/10.1182/blood-2023-187393

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Retrospective and Observational Study on CAR-T 19 Bridge Therapies in Pediatric, Adolescents and Young Adults <24 Years with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Experience of the Spanish Hematopoietic Stem Cell Trasplantation and Cellular Therapy Group (GETH-TC)

Víctor Galán-Gómez, Berta González-Martínez, Anna Alonso-Saladrigues, Susana Rives, Agueda Molinos Quintana, Jose Antonio Perez Simon, Blanca Herrero-Velasco, Mi Kwon, Pere Barba, Mario Sánchez-Salinas, Lucía López-Corral, Anna Torrent, Rafael Hernani, Odelaisy Leon Triana, Antonio Pérez-Martínez

Blood (2023) 142 (Supplement 1): 6909.

https://doi.org/10.1182/blood-2023-190471

Published: 2023

Journal Articles

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 267.

https://doi.org/10.1182/blood-2023-186388

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Blood (2023) 142 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2023-174115

Published: 2023

Journal Articles

Digital PCR Assay for Evaluation of CD19-CAR-T Cells In Vivo Expansion in Aggressive B-Cell Lymphoma: Impact on Clinical Outcome

Laura Ventura, Alicia Serrano, Blanca Ferrer Lores, Rafael Hernani, Alexandru Robert Vasile Tudorache, Ana Isabel Teruel, Ana Saus Carreres, Alfonso Ortiz Algarra, Ignacio Arroyo Martin, Juan Carlos Hernandez Boluda, Jose Luis Pinana Sanchez, Ariadna Perez, Ana Benzaquen, Carlos Solano, Maria Jose Terol Castera

Blood (2023) 142 (Supplement 1): 7153.

https://doi.org/10.1182/blood-2023-188300

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model

Blood (2023) 142 (Supplement 1): 5017.

https://doi.org/10.1182/blood-2023-185088

Published: 2023

Journal Articles

Digital Polymerase Chain Reaction (dPCR) Versus Flow Cytometry (FC), a Validation Study for CAR-T Cell Product Optimal Detection

Blood (2023) 142 (Supplement 1): 7152.

https://doi.org/10.1182/blood-2023-188216

Published: 2023

Journal Articles

Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Español De Trasplante y Terapia Celular (GETH-TC) Study

Blood (2023) 142 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2023-185721

Published: 2023

Journal Articles

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 378–380.

https://doi.org/10.1182/blood-2022-169219

Published: 2022

Journal Articles

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Blood (2022) 140 (Supplement 1): 1849–1851.

https://doi.org/10.1182/blood-2022-166329

Published: 2022

Journal Articles

Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 1592–1594.

https://doi.org/10.1182/blood-2022-169783

Published: 2022

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Blood (2022) 140 (Supplement 1): 665–667.

https://doi.org/10.1182/blood-2022-160000

Published: 2022

Journal Articles

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 2816.

https://doi.org/10.1182/blood-2021-147454

Published: 2021

Journal Articles

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Blood (2021) 138 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2021-147670

Published: 2021

Journal Articles

Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain

Blood (2021) 138 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2021-147369

Published: 2021

Journal Articles

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Gloria Iacoboni, MD, Josu Iraola-Truchuelo, Nuria Martinez-Cibrian, MD, Rebeca Bailén, MD, Lucia Lopez Corral, PhD MD, Jose M. Sanchez, MD, Manuel Guerreiro, MD, ANA Carolina Carolina CABALLERO González, Alberto Mussetti, MD, Juan-Manuel Sancho, MD PhD, Rafael Hernani, MD, Carlos Solano, MD PhD, Anna Sureda Balari, MD PhD, Javier Briones, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD, Mi Kwon, MD PhD, Juan Luis Reguera, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136201

Published: 2020

Journal Articles

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation

Blood (2019) 134 (Supplement_1): 5733.

https://doi.org/10.1182/blood-2019-126036

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Blood (2019) 134 (Supplement_1): 3325.

https://doi.org/10.1182/blood-2019-126507

Published: 2019

NARROW

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Retrospective and Observational Study on CAR-T 19 Bridge Therapies in Pediatric, Adolescents and Young Adults <24 Years with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Experience of the Spanish Hematopoietic Stem Cell Trasplantation and Cellular Therapy Group (GETH-TC)

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Digital PCR Assay for Evaluation of CD19-CAR-T Cells In Vivo Expansion in Aggressive B-Cell Lymphoma: Impact on Clinical Outcome

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model

Digital Polymerase Chain Reaction (dPCR) Versus Flow Cytometry (FC), a Validation Study for CAR-T Cell Product Optimal Detection

Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Español De Trasplante y Terapia Celular (GETH-TC) Study

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only